Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: London
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Silence Therapeutics PLC

+ Add to Watchlist

SLN:LN

305.000 GBp 11.000 3.74%

As of 11:35:22 ET on 04/24/2015.

Snapshot for Silence Therapeutics PLC (SLN)

Open: 295.000 Day's Range: 295.000 - 305.000 Volume: 24,818
Previous Close: 294.000 52wk Range: 168.000 - 307.000 1-Yr Rtn: +19.61%

Stock Chart for SLN

No chart data available.
  • SLN:LN 305.000
  • 1D
  • 1M
  • 1Y
294.000
Interactive SLN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for SLN

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. UKX -
Earnings Per Share (GBP) (ttm) -0.2200
Est. EPS (GBP) (12/2015) -0.2070
Est. PEG Ratio -
Market Cap (M GBP) 162.06
Shares Outstanding (M) 53.13
30 Day Average Volume 129,531
Price/Book (mrq) 5.7244
Price/Sale (ttm) 10,264.4554
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 09/21/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for SLN

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for SLN

Silence Therapeutics PLCis a European biotechnology company. The Company has developed a proprietary short interfering RNA(siRNA molecule). Silence also has developed a proprietary systematic delivery system to deliver molecules to targeted disease tissues and cells.

Ali MortazaviChief Executive OfficerTimothy Freeborn "Tim"Finance Director/Secretary
Michael Khan "Mike"Chief Medical Officer
More Company Profile & Key Executives for SLN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil